Financial Impact Of Grounded Flights Weighs Down Markets

|
Despite upbeat earnings news, the markets traded near the flatline with the Dow slipping 5 points to 11,086 over continued concerns about the financial impact of grounded flights in Europe. Nasdaq added 4 points to 2484.

On the upside

Array BioPharma (Nasdaq: ARRY) entered a collaboration agreement valued at up to $467 million with Novartis to develop the cancer treatments ARRY-162 and ARRY-300.

The European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion for CytRx's (Nasdaq: CYTR) chronic myeloid leukemia treatment bafetinib.

Argus upgraded Interpublic (NYSE: IPG).

On the downside

Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline (NYSE: GSK) announced that their lupus treatment Benlysta failed secondary goals in a late stage clinical trial.

First quarter earnings for Northern Trust (Nasdaq: NTRS) dropped to fall short of expectations.

MGIC Investment (NYSE: MTG) disappointed with a first quarter loss and the mortgage insurer announced a public offering of $700 million worth of common shares and $300 million in convertible senior notes.

In the broad market, advancing issues outpaced decliners by a margin of nearly 7 to 2 on the NYSE and by nearly 5 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks added 3 points to 714.

About this Entry

This page contains a single entry by published on April 20, 2010 6:49 AM.

Markets Rebound As Economic Indicators Index Jumps was the previous entry in this blog.

Upbeat Earnings Lift Markets is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12